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Alzheimer’s disease: from pathogenesis to biomarkers 
 
The term "dementia" currently indicates a syndrome which involves a progressive alteration of 
previously acquired cognitive functions of such severity that interfere with activities of daily living 
and quality of life. The skills implicated include attention, language, learning and memory, 
executive functions (i.e. programming skills, strategy development, problem solving, abstract 
thinking,), perception and social interaction; concomitant mood and behavior disorders contribute to 
complicate the clinical picture. This definition underlies a wide range of diseases that can be 
etiologically divided in primary (or degenerative) and secondary to defined causal factors, only a 
few of them curable. Degenerative dementia is classified in different irreversible forms, 
distinguishable from each other mainly through clinical features and supportive instrumental exams: 
in most cases a definitive diagnosis cannot be achieved in life. The improvement of scientific 
knowledge and the resulting development of increasingly precise criteria over the years has 
increased the specificity of the diagnosis of different form of dementia. Alzheimer's disease (AD) 
has been recognized as a clinical entity more than 100 years ago and represents the most frequent 
form of dementia (accounting for 60-80% of dementia cases) and the most common 
neurodegenerative disorder worldwide, affecting nearly 40 million people (Prince et al., 2013) of all 
races and ethnic groups. The high global prevalence and the economic impact on families, 
caregivers and society make AD a public health priority. Currently, two main forms of AD are 
recognized: a genetically determined familial form (FAD) that occurs in about 1-5% of AD cases 
and a sporadic late onset AD (LOAD) which is determined multifactorially and accounts for all the 
other cases. These two forms share underlying neuropathology, so the symptoms of both forms are 
similar. FAD is characterized by an early onset and associated with mutations in the amyloid 
precursor protein (APP) gene and the genes for presenilin 1 (PS1) or 2 (PS2), which are the 
components of γ-secretase complex responsible for cleavage and release of amyloid β (Aβ) from 
APP; this results in an imbalance between production and clearance of Aβ peptides and, as a 
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consequence, their accumulation in toxic aggregates in the brain, called amyloid plaques (Siegel GJ 
et al, 1999). Also neurofibrillary degeneration characterized by abnormal hyperphosphorylation and 
aggregation of protein tau (neurofibrillary tangles) plays a pivotal role in the pathogenesis of AD.  
 (Figure 1). 
 
Figure 1. Pathogenesis of Alzheimer’s disease.  
 
 
 
 
The formation of amyloid plaques and neurofibrillary tangles is thought to contribute to synaptic 
degeneration and neuronal loss resulting in atrophy of specific areas of the brain (entorinal cortex, 
hippocampus, amygdala, and basal telencephalus) (Auld et al., 2002) and the subsequent symptoms 
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of AD. Aß and tau are directly measurable in cerebrospinal fluid and reflect the amount of cerebral 
pathological aggregates of AD.   
LOAD is not clearly associated with any distinct mutation profile, although there is an increased 
likelihood of disease in carriers of a particular allelic form (ε4) of the apolipoprotein E that is a 
regulator of lipid metabolism with affinity for the Aβ protein aggregated in extracellular deposits, 
namely senile plaques (Strittmatter et al., 1993). 
The main known risk factor for the development of the sporadic form of AD is aging; indeed, the 
age-specific prevalence of AD almost doubles every 5 years after age 65 (Qiu et al., 2009). Another 
risk factor for developing dementia and AD is a clinical condition called Mild Cognitive Impairment 
(MCI) (Petersen et al., 2014). MCI, first described in 1999 (Petersen et al., 1999) but previously 
depicted with other terms (such as cognitive impairment not dementia, etc.), represents an 
intermediate stage between the expected cognitive decline of normal aging (and level of education) 
and the more pronounced decline of dementia; it is characterized by a slight but noticeable and 
measurable decline in cognitive abilities, not severe enough to interfere with day-to-day life and 
ordinary activities. MCI prevalence is around 15-20% in people aged 60 years and older with an 
annual rate of progression to dementia that varies between 8% and 15% per year (Petersen, 2016); a 
high frequency of subjects with MCI remains at that stage for years, others may even revert to 
normal cognition (Canevelli et al., 2016). Clinic-based studies have showed that up to 80% of 
subjects with MCI develop dementia after six years (Petersen, 2004). MCI that primarily affects 
memory function is known as "amnestic MCI", to distinguish it from "non-amnestic MCI" in which 
cognitive skills other than memory are affected; an additional distinction can be made between 
“single domain” and “multiple domain”. This classification by subtype relates not only to clinical 
presentation, but also to outcomes (and therefore to underlying aetiology and pathology), even if 
subtyping may depend on how extensive is the battery of neuropsychological tests applied. As 
shown in the figure 2, all different subtypes of MCI can be a prelude of AD. So MCI could be 
considered as a risk factor for AD, but at the same time, a prodromic phase of AD (figure 3).  
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Figure 2. Classification of Mild Cognitive Impairment in suptypes and implication for 
aetiology.  
 
 
                                                                             from Petersen et al., 2016 
 
Figure 3. Stages of Alzheimer’s disease.  
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In 2007, the International Working Group (IWG) for New Research Criteria for the Diagnosis of 
AD (Dubois et al., 2007) provided a new conceptual framework that proposes to integrate the 
clinical diagnosis of AD with the presence of biomarkers (Table 1).  
 
Table 1.  Putative Biomarkers for Alzheimer’s Disease Currently Being Used 
  
1. Markers of amyloid-beta (Aβ) protein deposition in the brain  
a. Low cerebrospinal fluid Aβ42 
b. Positive positron emission tomography amyloid imaging 
2. Markers of downstream neurodegeneration  
a. Elevated cerebrospinal fluid tau (total and phosphorylated) 
b. Decreased metabolism in temporal and parietal cortex on 18flurodeoxyglucose 
positron emission tomography 
c. Atrophy on magnetic resonance imaging in temporal (medial, basal, and lateral) 
and medial parietal cortex 
From Dubois et al., 2007 
 
The aim of these diagnostic criteria and of the subsequent National Institute on Aging–Alzheimer’s 
Association (NIA–AA) criteria of 2011 (McKhann et al., 2011), have been to expand coverage of 
the full range of dementia stages, from the asymptomatic through the most severe stages. 
Potentially, their most important practical application is to allow earlier intervention in the 
prodromal stage of the disease (such as MCI condition) and to facilitate research studies for 
secondary prevention of AD in a preclinical phase. NIA–AA criteria specified the criteria for 
making a diagnosis of “MCI due to AD” based on clinical criteria in combination with additional 
information from structural magnetic resonance imaging, FDG-PET, PIB-PET, and cerebrospinal 
fluid biomarkers.   
 
The term ‘biomarker’ is often used indiscriminately to describe any gene or protein expression 
change, but it has been better defined by the NIH Biomarkers Definitions Working Group as “a 
characteristic that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes or pharmacologic responses to a therapeutic intervention” (Marras 
et al., 2002). Several reports have examined the use and qualification of clinical biomarkers 
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(Freeman et al., 2010). More specifically, biomarkers for AD could be used for several objectives: 
diagnostic markers can be useful to recognize AD in a prodromal phase (MCI due to AD) and to 
differentiate this condition from different underlying etiologies, which will be important for 
choosing a correct treatment, when effective therapy is available; prognostic markers may define the 
likelihood of cognitive and functional progression (potentially a defined period of time) for MCI to a 
more severe stage of MCI (from single to multiple domain) or to dementia; finally, staging markers 
are helpful to describe disease severity and theragnostic markers to support treatment choice. A 
biomarker which might be useful for defining an aetiology could not be beneficial for characterizing 
a prognosis and vice versa. So, different properties of biomarkers may have differential utility over 
the short- and long-term and this knowledge should drive their use in the research and clinical 
context (Albert et al., 2011). 
In 2014 IWG-2 criteria reconsidered the biomarker support necessary for AD diagnosis by 
anchoring all diagnostic criteria to the need of in-vivo evidence of AD pathophysiology; an 
important change in IWG-2 criteria is that topographical markers of AD were recommended as 
staging rather than as diagnostic markers (Table 2).  
 
Table 2. Comparison of the IWG-2 and NIA-AAA criteria 
 
 
From Molin et. al, 2016 
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Body composition as a potential biomarker in Alzheimer’s 
disease 
 
Among systemic manifestations of AD which still do not find a unique interpretation, progressive 
weight loss (WL) has been described for the first time by Alois Alzheimer himself in 1907, who 
recognized a "slow progressive decline in body weight" in his first patient. Since then, several 
studies in the Eighties have confirmed in a large subpopulation of AD patients a non-intentional WL 
and a malnutrition, resulting in a change of body composition (Asplund et al., 1981; Cronin-Stubbs 
et al., 1997); in 1984 WL was even listed in NINCDS-ADRDA criteria of AD (McKhann et al., 
1984).  
Since 2005, reversible acetylcholinesterase inhibitors have been introduced for the symptomatic 
treatment of AD; adverse events consistent with the cholinergic actions of these drugs include loss 
of appetite and nausea, which doubtless can impact on food intake. However, a study of 1997 
highlighted that WL in naïve patients with AD (0.52 kg/m2/year) was higher than that of elderly 
non-dementia patients (0.14 kg/m2/year). Moreover, a study conducted in 2013 in over 300 AD 
patients with a maximum follow-up of about 3 years, showed that long-term treatment with 
galantamine had no effect on weight (Droogsma et al., 2013).  
Several mechanisms are hypothesized at the basis of WL (Sergi et al., 2013) it could be explained by 
the presence of a hypermetabolism and/or a reduction in energy intake and/or an increased physical 
activity; etiological factors that may support each of these hypotheses are illustrated in Figure 4.   
 
 
 
 
 
 
 
 
  
10 
 
Figure 4. Mechanisms potentially causing a weight loss in Alzheimer's disease. 
 
 
 
MTC, medial temporal cortex; ACC, anterior cingulated cortex; MTL, medial temporal lobe; IPL, inferior parietal lobe; 
LTN, lateral temporal neocortex; PC, prefrontal cortex; CCK, cholecystokinin 
From Sergi et.al, 2013 
 
 
Amyloidogenesis and neurofibrillary degeneration may be associated with progressive WL by three 
hypothetical mechanisms: 
 
1) Increased physical activity and, consequently, energy consumption. 
One of the first clinical signs of AD consists on the loss of episodic memory, a disorder that results 
in ineffective storage of new information: patients become restless, are committed in repetitive tasks  
(Lopez et al., 1999) and spend more energy in trying to carry out everyday activities. Apathy, 
spatial-temporal disorientation (which contributes to increased physical exercise and walking) and 
anxiety resulting from the perception of the AD patient’s difficulties also contribute to the increase 
in energy expenditure. In advanced stages of AD, the occurrence of aberrant motor activity (e.g. 
wandering) is frequently observed; patients also frequently exhibit psychotic behavioural symptoms 
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such as agitation and aggression, and these symptoms have been associated to a WL of more than 5 
kg during a 6-month follow-up (White et al., 2004). The hypothesis of an increased energy 
consumption as the cause of the WL is most attributable to behavioural disorders of advanced stage; 
this assumption however is in contrast with the demonstration that weight reduction appears more 
pronounced in the initial stage of AD (0.59 kg/m2/year) rather than in the severe stage (0.47 
kg/m2/year) (Cronin-Stubbs et al., 1997).  
 
2) Reduced energy intake due to poor food intake. 
AD patients may forget to eat or experience aversion to some food (Miyamoto et al., 2011). 
Cognitive deficits affect the ability to provide, to purchase and to prepare food (Tracy et al., 2001). 
Progressive lifestyle changes may eventually lead to depart from a healthy diet regime. Earlier 
changes in appetite-regulating mechanisms have also been described, namely a decreased ability to 
smell and a loss of taste possibly due to amyloid plaques in brain areas responsible for these 
functions (cingulate cortex, olfactory epithelium); a premature sense of satiety may be caused by a 
higher sensitivity to cholecystokinin (Morley, 2001). Reduction in dietary intake may also be caused 
by neuroinflammation through the production of pro-inflammatory cytokines (TNFɑ, IL-1, IL-6) 
which reduce hunger, by possibly concomitant mood deflection and/or chronic therapies which can 
lead to anorexia, constipation and further contribute to decreasing the sense of taste and smell 
(Plata-Salamán, 1996; Kishi and Elmquist, 2005). 
With the progression of dementia and functional deficits, caregivers support becomes increasingly 
important to provide adequate energy intake to the patient; they can offset the patient’s 
difficulties by purchasing food, preparing meals, modifying a food’s consistency to make it simpler 
to swallow. Indeed during advanced stages, patients may experience difficulty in carrying food to 
their mouths and in chewing, thus contributing to weight loss (Berkhout et al., 1998).  
A discrepancy between needs, intake and nutrient utilization entails a state of functional and 
structural alteration of the body, which is defined as malnutrition. This clinical condition, which 
may occur due to poor or inadequate dietetic regimen as well as to deficiency or excess of certain 
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nutrients, is most frequently observed in advanced age. The Mini Nutritional Assessment (MNA) is 
a validated nutrition screening test for the elderly population, consisting of 18 questions, divided 
into 3 sections: anthropometry (body mass index [BMI], arm and calf circumference, weight loss), 
eating habits (number of full meals per day, fluid introduced, vegetables, fruit and protein intake, 
mode of feeding), cognitive status and disability (mobility, psychological stress or acute illness, 
neuropsychological problems, prescription drugs per day, pressure sores or skin ulcers, self view of 
nutritional status and health). Scores <17 indicate malnutrition, scores between 17 and 23.5 indicate 
risk of malnutrition and scores ≥ 24 indicate a normal nutrition. The prevalence of malnutrition in 
community-dwelling elderly studied with MNA (21 studies, n = 14149 elderly) was around 2% and 
risk of malnutrition around 24 % (Guigoz, 2006). A Dutch study conducted in 2014 found no 
significant differences of MNA scores between mild AD patients and healthy elderly controls; 
however, mean scores of MNA in AD resulted lower than cut-off of normal nutritional status (< 
24.0), suggesting an increased risk of malnutrition only in a subgroup of AD (Olde Rikkert et al., 
2014). These results are in agreement with those of another Dutch study (Droogsma et al., 2013) that 
showed that AD patients did not suffer from protein-energy malnutrition, with the exception of a 
subgroup of patients (14%) at risk for malnutrition (MNA scores 17-23.5). Several studies showed a 
positive association between the risk of malnutrition and later stages of AD (Sandman et al., 1987; 
Guerin et al., 2005; Gillioz et al., 2009; Buffa et al., 2010; Droogsma et al., 2013).  
 
3) Hypermetabolism  
Among the several biological factors thought to be involved in the onset and progression of AD, an 
important role could be played by an imperfect functioning of mitochondria. These organelles are 
the energetic centers of the cell due to their main function of ATP production through the coupling 
of the electron-transport system with phosporylation. During simultaneous exposure to amyloid β 
and phosphorylated tau, conformational, alterations in electrical potential and mobility, as well as 
different response to oxidative stress of mitochondria in neurons of rats have been described 
(Quintanilla et al., 2012). Mitochondrial dysfunction could justify the reduction of cerebral 
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metabolism, especially in the temporal-parietal cortex typically involved in AD (Sullivan and 
Brown, 2005). Mitochondria actually supply brain cells with about 90% of the total required energy 
(Wallace, 1997). A decoupling of the electron-transport system, which is a distinctive feature of 
brown adipose tissue, leads to a lower ATP production whilst heat production increases; this 
mechanism represents a cytoprotective strategy occurring during aging process in order to reduce 
the production of free radicals (Speakman et al., 2004). However, decoupling in altered 
mitochondria may increase the production of free radicals, inducing cellular damage and increasing 
the permeability of the mitochondrial membrane to H+ ions, thus supporting the decoupling process 
in a vicious circle (Brookes, 2005). An increased mitochondrial oxidative activity in muscle tissue 
of AD patients with respect to controls have been found in a study of 1991 (Mariani et al., 1991). In 
2004, AD mitochondrial cascade hypothesis has been proposed as a key for interpretation of 
amyloid cascade in sporadic late-onset AD: mitochondrial dysfunction could trigger APP expression 
and processing or Aβ accumulation. This hypothesis suggested that gene inheritance defines an 
individual's baseline mitochondrial function; inherited and environmental factors determinate rates 
at which mitochondrial function changes over time: so baseline mitochondrial function and 
mitochondrial change rates could influence brain aging as well as AD chronology (Swerdlow and 
Khan, 2004).  
Hypermetabolism would also seem to be increased by neuroinflammation: amyloid deposits are able 
to activate astrocytes and microglia in the production of cytokines, leading to a systemic 
inflammatory response (Visser et al., 2002; Rebeck et al., 2010; Patra and Arora, 2012).  
Pro-inflammatory molecules are released also from microbiota, due to changes in permeability of 
the gut due to chronic stress (Rieder et al., 2017), thus affecting functions of microglia; microbiota 
seems also implicated in the regulation of the formation of amyloid plaques (Fung et al., 2017).  
 
Many stressors have been suggested as initiators of AD neuropathology ( Figure 5)  
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Figure 5. From stressors to Alzheimer’s disease-related neuropathology. 
 
 
From Mravec et al, 2017 
 
 
Chronic and/or psychosocial and physical stressors can contribute to neuroinflammation through a 
mechanism of activation of signals processed by neurons synthesizing glutamate, norepinephrine 
from locus coeruleus, corticotropin-releasing factor (CRF), other neurotransmitters and 
neuromodulators. Repeatedly or chronically elevated mediators of the neuroendocrine stress 
response have a direct damaging role on the brain by impairing neuronal metabolism, plasticity and 
survival (Mravec et al., 2017).  (Figure 6)  
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Figure 6.  Development of Alzheimer’s disease phenotype as a consequence of a multistep-
pathological cascade activated by primary etiological factors. 
 
From Mravec et al, 2017 
 
 
The effector molecules of the hypothalamic–pituitary–adrenal  axis are glucocorticoids (GC) which 
exert pivotal effects such as regulation of glucose utilization by brain tissue, appetite, feeding and 
memory formation (Sapolsky et al., 2000). High density of GC binding receptors is known in 
hippocampus; whereas central role of GC is to maintain homeostasis, a persistent elevated level of 
GC due to chronic stress could instead reduce synaptic plasticity and the number of neurons in 
hippocampus, by damping of brain-derived neurotrophic factor (Lucassen et al., 2015). Moreover, 
through the activation of glycogen synthase kinase-3, high GC increases phosphorylation of tau (Yi 
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et al., 2017). Some recent evidences also suggest a potential neuroinflammatory role of GC (in 
contrast to their classical view) (Vyas et al., 2016) (Figure 7). 
 
 
Figure 7. Cellular targets and actions of chronic stress mediated by glucocorticoid receptors. 
 
From Vyas et al. , 2016 
 
 
GC lead to orexigenic effects and insulin resistance: changes in the hormonal regulation of energy 
metabolism can then contribute to alteration in body weight. Insulin resistance and AD are linked 
also by other factors, for example the increased levels of specifically phosphorylated insulin 
receptor substrate 1, coexpression of AD- and insulin resistance-related genes and insulin-
modulating degradation of β amyloid (Diehl et al., 2017). It has been hypothesized that AD may 
represent a metabolic disease and has subsequently been referred to as ‘‘type 3 diabetes’’ 
(Kandimalla et al., 2017) (Figure 8). 
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Figure 8. Insulin signalling pathway in healthy and AD brain.  
 
 
 
From Kandimalla et al, 2017  
 
 
 
In conclusion, the third mechanism (hypermetabolism) is the most convincing interpretation of 
weight loss in the initial phases of AD process, but additional factors may play a complementary 
role.  
In a recent study from our group, MCI who lost ≥ 4% of their body weight during follow-up had a 
3.4-fold increased risk of dementia and a 3.2-fold increased risk of AD; on average, weight loss 
was associated with a 2.3 and 2.5 years earlier onset of dementia and AD (Cova et al., 2016b). 
This is in agreement with previous findings which showed a 30–40% weight loss in mild to 
moderate AD patients (White et al., 1996; Gillette-Guyonnet et al., 2000) and with studies 
suggesting that weight loss begins several years before the diagnosis of AD (Stewart et al., 2005; 
Johnson et al., 2006). It is also consistent with the results from a population-based study which 
found that amnestic MCI who lose weight undergo faster functional decline after one year (Besser et 
al., 2014).  So, weight loss could be a predictor of the progression of MCI to dementia and AD.  
The measurement of body weight, however, does not allow to distinguish between the various 
components of the body mass; there are several more precise methods to measure nutritional status. 
Body mass index (BMI) is the most widely used indicator of overweight and obesity and has a 
robust correlation with body fat percentage (Lichtash et al., 2013); it is calculated by dividing 
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weight (in kilograms) for height squared (in centimeters). BMI also suggests a relationship between 
body parameters and mortality risk in general population: a lower relative risk of death is described 
with values between 18.5 and 24.9 (normal weight), a higher risk is present if values are below 18.5 
(underweight) and the risk grows almost exponentially with the increase of BMI over values of 25 
(overweight and obesity) (Prospective Studies Collaboration et al., 2009). However, BMI has 
limited accuracy since it does not discriminate the relative contribution of muscle mass and body fat 
to overall weight; BMI is then used in association with other body measures (Okorodudu et al., 
2010). Arm and calf circumferences are useful instruments to evaluate nutritional status: an arm 
circumference lower than 23 cm in men and 22 cm in women, as well as a calf circumference lower 
than 31 cm in both sexes increases the risk of malnutrition (Guigoz, 2006). 
Waist circumference is directly related to visceral fat tissue. (WHO, 2008). The muscular tissue is 
directly proportional to the lean mass and reveals the basal metabolism of each subject, namely the 
energy spent at rest (i.e. 45-75% of the total energy expenditure). Basal metabolism can be 
calculated with predictive equations or by calorimetric (direct and indirect) and non calorimetric 
methods. Direct calorimetry evaluates the energy expenditure by measuring the heat dispersion of a 
subject within a metabolic chamber; it is the most accurate method but it is very expensive and not 
applicable at outpatient level due to its complexity. Indirect calorimetry measures energy 
expenditure through variations in oxygen and carbon dioxide concentrations in respiratory gases and 
calculates the oxidation of energy substrates; it is rather imprecise since it does not detect the 
differences between glucidic and lipidic substrates. 
The Dual Energy X-ray Absorptiometry (DEXA) can be used to calculate the various components of 
the body mass: mineral bone density, lean mass, cellular mass and, indirectly, fat mass. Hydrostatic 
Weighing is another expensive exam able to detect the displacement of water generated by a 
submerged body to measure its density and from that figure calculate percentage body fat. 
Plicometry is a simpler but unreliable method to measure the fat mass through skin folds (Walter-
Kroker et al., 2011).  
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Bio-Impedance Analysis (BIA) is a non-invasive technique which discriminates between lean and 
fat mass (as percentages); it is based on the principle that different tissues express a specific 
electrical conductivity and offer a dissimilar resistance to the passage of current: adipose tissue 
proffers a high resistance while muscular tissue a low resistance (since its highest content of water) 
(Walter-Kroker et al., 2011). Different resistances are detected and transformed through appropriate 
equations in the parameters shown in Figure 9. 
 
 
Figure 9. Analysis of the 2-compartmental body composition. 
 
 
 
 
 
FFM
TBW
FM ATM BCM
ICW ECW
 
 
 
 
 
 
 
Fat Free Mass (FFM); Fat Mass (FM); Body Cell Mass (BCM); Extracellular Mass (ECM); Total Body Water (TBW); 
Intracellular Water (ICW); extracellular water (ECW); Lean Body Mass (LBM).  
 
 
Empirical formulas of BIA are obtained by means of statistical calculations from healthy subjects 
but are based on the hypothesis that hydration of lean mass is a fixed percentage (estimated at 73%); 
any condition associated with a different hydration can thus introduce a distortion in compartmental 
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estimations with an unpredictable propagation of the error affecting the entire body composition 
analysis, especially in the elderly and/or in pathological subjects. 
A variant of the BIA, called bioelectrical impedance vector analysis (BIVA) (Piccoli et al., 1994), is 
a more accurate method because it does not require the use of predictive equations. It is a stand-
alone procedure based on patterns of direct impedance measurements (impedance vectors). 
Impedance (Z vector) is a combination of Resistance (R), which expresses the opposition of intra- 
and extracellular body fluids to flow of an alternating current, and Reactance (Xc) which consists in 
the capacitative component of tissues. R negatively correlates with the quantity of ionic solutions, 
Xc is directly related to the amount of soft tissue structures. The vectors of each subject are 
compared with a reference population and described as percentiles of a normal distribution of a 
probabilistic bivariate graph. Unlike BIA, BIVA method does not estimate any body compartment; 
the length and position of the Z vector supplies information about the state of hydration and body 
cell mass. The length of the vector indicates the level of hydration, from fluid overload (shorter 
vector: decreased resistance) to bodily dehydration (longer vector: increased resistance). Lateral 
vector displacements due to high or low reactance denotes an increase or a decrease of dielectric 
mass (membranes and tissue interfaces) of soft tissues. The phase shift of the tissue interfaces, called 
phase angle (PA), represents both the quantity and quality of soft tissue and can be calculated 
directly as arctan (Xc/R). Clinically it is the most important impedance parameter, predicting 
morbidity and mortality in a variety of diseases; higher values of PA correspond to a higher 
cellularity and a better cell membrane integrity; PA decreases with age and is significantly lower in 
women, due to the (physiologic) lower amount of body muscle (Norman et al., 2012). 
Table 3 summarizes the studies focusing on the analysis of body composition in AD and healthy 
controls through various methods, including the two studies using the BIVA detailed below (Buffa 
et al., 2010, 2014). 
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Table 3 Case-control studies (AD vs. HC) evaluating the composition of body mass with 
different methods.  
Studies Population Methods Results 
Renvall et al., 
1993 
28 HC 
23 institutionalized AD  
BMI 
BIA  
Hydrostatic weighting in 
6 HC 
♀AD vs. HC: < BMI,  > % FFM, < % FM, > 
% TCW 
♂AD vs. HC: < BMI 
(no differences in body composition) 
Wolf-Klein et al., 
1995 
7 HC 
5 mild-moderate AD  
4 severe institutionalized AD 
5 severe institutionalized 
multi-infarct dementia (MID) 
Indirect calorimetry Mild-moderate AD vs. HC:  
> energy requirement, different pattern FFM  
Non institutionalized AD vs. MID:  
> weight loss, > energy requirement 
Donaldson et al., 
1996 
75 HC 
25 non institutionalized AD  
Indirect calorimetry 
DEXA  
AD vs. HC: no differences in basal 
metabolism, FFM, FM 
(Spindler et al., 
1996) 
23 HC 
17 AD 
Computer program 
(Body Composition II, 
version 1.0, 1987)  
♀AD vs. HC: < BMI,  > % FFM 
♂AD vs. HC: no differences in BMI / body 
composition 
(Poehlman et al., 
1997) 
103 HC 
30 AD 
Indirect calorimetry 
DEXA  
AD vs. HC: <FFM 
No differences in FM e basal metabolism 
(Gillette-Guyonnet 
et al., 2000) 
32 ♀ HC 
32 ♀ AD 
DEXA No differences in FFM (trend < FFM in AD) 
Burns et al., 2010 70 HC 
70 mild AD  
DEXA AD vs. HC: <FFM  
Buffa et al., 2010 468 HC 
83 mild-moderate AD  
9 institutionalized AD 
BIVA 
Mini Nutritional 
Assessment 
AD vs. HC: < PA  
In severe AD: > Z  
Buffa et al., 2014 560 HC 
70 AD 
Specific BIVA 
Mini Nutritional 
Assessment  
AD vs. HC: < BCM, > ECW/ICW, > % FM  
No differences in MNA between AD and HC 
 
HC= healthy controls; AD = Alzheimer’s disease patients; BCM=Body Cell Mass; ECW=Extracellular Water; FFM=Fat 
Free Mass; FM=Fat Mass; PA=Phase Angle; TCW=Total Body Water; Z=Impedance.  
 
Buffa et al., are the first group which has used the BIVA method to study nutritional status in AD 
subjects (Buffa et al., 2010, 2014). In their studies they have shown that AD had a significant lower 
PA, namely a lower BCM; no other group have so far replicated their data. No body composition 
studies in MCI subjects are yet available; it is likely that a different assessment of body 
compartments can be detectable before a clinical evident AD, namely at the stage of MCI due to 
AD. In such a case, the use of a simple screening tool such as BIVA could identify subjects with 
MCI most at risk of progressing to AD. 
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Aims of the study  
 
Cross-sectional part 
To analyze nutritional and body composition differences between AD, MCI and HC in order to 
identify a possible AD diagnostic marker. 
 
Longitudinal part 
To verify if any differences in nutritional and/or body composition parameters suggested from the 
cross-sectional part of the study could serve also as a staging biomarker of AD. 
To verify if any differences in nutritional and/or body composition parameters suggested from the 
cross-sectional part of the study could serve also as a prognostic biomarker of MCI. 
 
 
Materials and Methods 
 
Subjects and design 
This study was carried out in the Center for Research and Treatment on Cognitive Dysfunctions of 
the Luigi Sacco Hospital, University of Milan.  
The study protocol was approved by the Sacco Hospital Ethics Committee and informed written 
consent from all subjects was obtained by the principal researcher, after neuropsychological 
assessment of the patients' capacity to provide a consent. 
We enrolled outpatients consecutively admitted from December 2014 to January 2016 with a 
diagnosis of MCI (by NIA-AA criteria (Albert et al., 2011) or mild to moderate probable AD with 
increased level of certainty with a documented decline (by NIA-AA criteria (McKhann et al., 2011). 
Cognitively healthy controls (HC) were enrolled in the same period and consisted of patients’ 
  
23 
spouses or relatives of Neurology department inpatients (hospitalized due to acute disease of CNS, 
such as stroke) and outpatients. 
Subjects were excluded if aged < 65 years, if they had pacemakers, heart defibrillators or other 
electrical implants and if they were suffering from a known active cancer.   
All study participants underwent an evaluation following a standardized protocol. Collected data 
included demographic characteristics, medical history, present and previous pharmacological 
treatments. MCI and AD participants were also evaluated with an extensive neuropsychological 
assessment (Cova et al., 2016a), clinical and neurological examination, standard laboratory blood 
tests and neuroimaging (MRI or CT scan). In our center, AD patients are usually requested to return 
every 6 months for clinical follow-up visits to monitor cognitive status, level of functioning based 
on information from caregivers and subsequently adjust therapies. MCI are follow-up annually by 
repetition of neuropsychological tests.  
HC underwent cognitive screening with Mini Mental State Examination (MMSE) (Folstein et al., 
1975) and mood evaluation with 30-items Geriatric Depression Scale (GDS) (Yesavage et al., 
1982). 
 
Nutritional evaluation 
Nutritional evaluation was performed at baseline for all the subjects and repeated at follow-up in AD 
patients by means of anthropometry, Mini Nutritional Assessment (MNA) and bioelectrical 
impedance vector analysis  
Anthropometric measurements were taken by the principal researcher following standard criteria 
(Timothy G, Lohman, Alex F. Roche, Reynaldo Martorell, 1988). Height (cm) was measured with 
an anthropometer and weight (kg) with a mechanical beam scale; body mass index (BMI) (kg/m2) 
was hence calculated. Body circumferences (waist, mid arm and calf) were obtained with an 
inelastic plastic-fiber tape measure (to the nearest 1 cm); the waist was measured midpoint between 
the lowest rib and the upper border of the iliac crest; the mid arm was measured at the midpoint 
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between the lateral tip of the acromion and the most distal point on the olecranon; the calf was 
measured at the maximum girth (Al-Gindan et al., 2014). 
MNA (Guigoz, 2006) as previously described, is an 18-item tool used to assess nutritional risk in 
elderly, grouped in 4 rubrics: anthropometric assessment (BMI, weight loss, arm and calf 
circumferences; items B, F, Q and R ); general assessment (lifestyle, medication, mobility and 
presence of signs of depression or dementia; items C, D, E, G, H and I); short dietary assessment 
(number of meals, food and fluid intake, and autonomy of feeding; items A, J, K, L, M and N); and 
subjective assessment (self perception of health and nutrition; items O and P). Each answer has a 
numerical value and contributes to the final score, which reaches a maximum of 30; AD patients 
were helped to complete it by their caregivers. MNA screening (sum of items from A to F), global 
(sum of items from G to R) and total score were collected.  
Bioimpedance measurements were carried out in subjects fasting for at least three hours. The 
bioelectrical variables of resistance (R, Ohm) and reactance (Xc, Ohm) were measured with a single 
frequency impedance analyzer (EFG-ElectroFluidGraph; AKERN-Srl, Florence, Italy).  
The accuracy was checked with a calibration circuit of known impedance (R: 383 Ohm, Xc: 45 
Ohm, 1% error). Moreover, test–retest reliability over a time interval of 14 days was checked in a 
group of 15 healthy controls. 
Whole body impedance measurements were taken using the standard positions of outer and inner 
electrodes on the right hand and foot (Anon, 1996). The length of the impedance vector (Z) was 
calculated by the equation Z= (R2+Xc2)0,5 and the phase angle (PA) by arctan (Xc/R). The R, Xc and 
Z values were divided by the subject’s height (H) to remove the effect of conductor length (Piccoli 
et al., 1994).  
Impedance measurements standardized by height were represented as bivariate vectors with their 
confidence intervals, which are ellipses in the R-Xc plane.  
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Covariates 
Potential confounders included personal data, such as age, sex, years of education, MMSE score, 
GDS score, smoking habits (previous smoker, actual smoker, no smoker). Somatic comorbidities 
were quantified using the Modified Cumulative Illness Rating Scale (CIRS) (Salvi et al., 2008). The 
modified CIRS includes 14 categories assessing the impairment of each organ system, with a score 
ranging from 0 to 4. The total score was calculated by adding the scores from each of the 14 
individual system scores. The “CIRS comorbidity index”, based on the sum of CIRS items with 
scores ≥ 2 (indicating moderate disability or morbidity and/or requirement of first line therapy) was 
also calculated. We evaluated comorbidities with particular emphasis on disease and treatments 
which could play a role in body composition, such as diabetes mellitus, dysthyroidism 
(hypothyroidism or hyperthyroidism), depression (clinical depression with/without treatment and/or 
GDS score ≥ 11), use of antihypertensives, especially diuretics, oral hypoglycemic agents, insulin, 
levothyroxine and antidepressants. 
 
Statistical Analysis 
Subjects’ characteristics among the three groups of participants (HC, MCI and AD subjects) were 
compared separately for males and females as previously proposed (Anon, 1996; Buffa et al., 2010) 
using univariate ANOVA test for continuous variables and Pearson’s χ2 test for categorical 
variables. Post hoc analyses with Bonferroni correction were performed when appropriate. 
Multivariate analyses with general linear models were then carried out, with nutritional indicators, 
anthropometric and bioelectrical variables as the dependent variable, the dementia diagnostic 
category (normal, MCI, and AD) as group and other significant demographic and psycho-functional 
variables emerged in previous univariate analyses as potential confounding variables as covariates.  
Three general linear models (GLM) were carried out: unadjusted, partially adjusted (for 
sociodemographic variables such as age, gender and education) and fully adjusted (for 
sociodemographic variables and psycho-functional status). 
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The differences between the mean impedance vectors in AD, MCI and HC groups were assessed 
with Hotelling’s T2 test, a multivariate extension of the univariate t-test and graphically with 95% 
probability confidence ellipses. Non-overlapping 95% confidence ellipses correspond to statistically 
significant difference between mean vector displacements on the R-Xc plane (P < 0.05, which 
corresponds to a significant Hotelling’s T2 test, that is equivalent to a significant difference in R, Xc 
or both parameters).  
Mahalanobis D distance (D) among mean vectors, which uses within-groups variation (elliptical 
shape) as a yardstick for differences between means, was also calculated.  
Nutritional variables of AD group at baseline and follow-up were analysed by Wilcoxon test and 
linear regression analysis within gender.  
MCI subjects’ characteristics at baseline were compared by outcome using the Mann-Whitney test 
for continuous variables and Pearson’ s χ2 test for categorical variables. 
All p values <0.05 were regarded as statistically significant. SPSS for Windows (version 23.0) was 
used for statistical analyses. BIVA was performed with an open source specific software (Piccoli 
and Pastori, 2002).   
 
Results  
 
Cross-sectional part of the study 
 
Table 1 and 2 show psycho-functional, anthropometric, multidimensional and bioelectrical variables 
in healthy controls (HC), Mild Cognitive Impairment (MCI) and Alzheimer’s disease (AD), 
respectively in men and in women.  
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Table 1. Descriptive and comparative statistics for the psycho-functional, anthropometric, 
multidimensional and bioelectrical variables in healthy controls (HC), Mild Cognitive 
Impairment (MCI) and Alzheimer’s disease (AD) men.  
 
 
HC (N=29) MCI (N=14) AD (N=24) F Post Hoc § 
 Demographic variables 
     
Age (y) 74.3 ± 5.3 78.6 ± 4.4 77.5 ± 8.2 2.85 
 
Education (y) 10.2 ± 3.9 10.1 ± 4.8 9.7 ± 3.8 0.11  
Psycho-functional indicators 
     
MMSE score 29.2 ± 0.9 25.1 ± 2.5 19.7 ± 4.4 68.78*** AD<MCI <HC 
GDS scorea 6.6 ± 3.6 5.1 ± 3.6 11.8 ± 5.1 7.34*** HC=MCI<AD 
ADL (functions lost) 0.0 ± 0.0 0 ± 0 1.6 ± 1.8 16.73*** AD<MCI=HC 
IADL (functions lost) 0.0 ± 0.0 0.7 ± 0.1 3.5 ± 1.7 159.29*** AD<MCI=HC 
Nutritional indicators 
     
MNA screening score 13.9 ± 0.4 12.9 ± 1.3 11.9 ±1.2 24.78*** AD< MCI<HC 
MNA global score 14.2 ±1.1 14.2 ± 1.3 12.2 ± 1.4 19.06*** AD<MCI=HC 
MNA total score 28.0 ± 1.1 27.1 ± 1.9 24.1 ± 2.3 33.04*** AD<MCI=HC 
Anthropometric variables      
BMI (kg/m2) 26.6 ± 2.5 26.5 ± 3.0 24.8 ± 3.0  3.12   
Arm circumference (cm) 26.9 ± 2.8 26.1 ±2.0 24.0 ± 3.0  7.96** AD<HC 
Calf circumference (cm) 35.2 ± 2.8 33.6 ± 3.1 32.9 ± 2.3  4.86* AD<HC 
Waist circumference (cm) 96.7 ± 7.9 99.1 ± 9.4 90.4 ±10.6  4.86* AD<MCI 
Bioelectrical variables 
     
Rz/h (Ώ/m) 231.8 ± 23.8 261.0 ± 34.2 260.6 ± 35.4  7.29** HC<MCI=AD 
Xc/h (Ώ/m) 26.7 ± 3.2 29.5 ± 6.5 27.2 ± 4.8   1.77  
PA (°) 6.6 ± 0.7 6.4 ± 0.7 5.9 ± 0.6   6.39** AD<HC 
Z/h (Ώ/m) 233.3 ± 23.9 262.0 ± 34.6 262.1 ± 35.6   7.20** HC<MCI=AD 
 
Values are expressed as mean ± standard deviation 
§Only significant differences are shown a available for HC, MCI and 28 % AD group. * p<0.05 ** p<0.01  *** p< 0.001 
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Table 2. Descriptive and comparative statistics for the psycho-functional, anthropometric, 
multidimensional and bioelectrical variables in healthy controls (HC), Mild Cognitive 
Impairment (MCI) and Alzheimer’s disease (AD) women.  
 
 
Values are expressed as mean ± standard deviation. 
§only significant differences are shown a available for HC, MCI and 14,3 % AD group* p<0.05 ** p<0.01 *** p< 0.001 
♯
 multivariate general linear model (adjusted for age)  
 HC (N=29) MCI (N=20) AD (N=35) F Post Hoc § F ♯ 
Demographic variables       
Age (y) 75.1 ± 6.4 76.9 ± 4.5 82.1 ± 4.8 14.82*** HC<AD; MCI<AD  
Education (y) 8.0 ± 3.4 6.5 ± 3.5 6.1 ± 3.3 2.46  3,81* 
Psycho-functional indicators       
MMSE score 29.2 ± 0.9 25.9 ± 2.5 18.9 ± 4.9 75.42*** AD<MCI; MCI<HC 50,12*** 
GDS scorea 7.6 ± 4.0 10.7 ± 5.6 7.6 ± 5.0 2.56  1,96 
ADL (functions lost) 0.0 ± 0.0 0.0 ± 0.0 1.9 ± 1.8 27.09*** HC=MCI<AD 21,87*** 
IADL (functions lost) 0.0 ± 0.0 0.3 ± 0.6 5.0 ± 2.0 104.93*** HC<MCI<AD 102,38*** 
Nutritional indicators       
MNA screening score 12.7 ± 1.4 12.4 ± 2.4 11.8 ± 1.4 2.24  2,02 
MNA global score 14.4 ± 1.1 13.0 ± 1.4 11.6 ± 1.7 28.80*** AD<MCI <HC 19,90*** 
MNA total score 27.1 ± 4.5 25.4 ± 3.1 23.4 ± 2.7 16.62*** AD<HC 12,11*** 
Anthropometric variables       
BMI (kg/m2) 27.2 ± 4.5 25.8 ± 4.3 25.1 ± 3.9 1.87  1,88 
Arm circumference (cm) 26.9 ± 3.2 25.4 ± 2.8 25.0 ± 3.1 3.02  3,07* 
Calf circumference (cm) 33.9 ± 2.8 33.1 ± 2.7 30.9 ± 3.5 7.68** AD<HC=MCI 5,58** 
Waist circumference (cm) 93.0 ± 12.2 86.4 ± 9.5 86.4 ± 10.5 3.48  2,37 
Bioelectrical variables       
Rz/h (Ώ/m) 286.8 ± 34.3 303 ± 38.2 311.9 ± 30.9 4.40* HC<AD 3,30* 
Xc/h (Ώ/m) 30.2 ± 4.1 29.3 ± 3.4 29.5 ± 5.0 0.30  4,71** 
PA (°) 6.1 ± 0.6 5.6 ± 0.6 5.4 ± 0.7 6.39* AD<HC 17,54*** 
Z/h (Ώ/m) 288.4 ± 34.4 305 ± 38.2 313.4 ± 31.0 7.20* HC<AD 3,21* 
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Sociodemographic variables did not differ among AD, MCI and HC, except for females’ age (HC 
<AD; MCI <AD), therefore age was used as covariate in a multivariate GLM (Table 2). AD were 
enrolled after 68.1 ± 12 months and MCI after 64.1 ± 43.5 months from the onset of cognitive 
impairment.  
AD, MCI and HC were similar in terms of factors potentially confounding the relationship between 
body composition and dementia process (smoking habit, diabetes mellitus, use of oral hypoglycemic 
agents/insulin, dysthyroidism, use of levothyroxine, use of diuretics/other antihypertensives, use of 
antidepressants), with the exception of clinical depression which was more prevalent among women 
with MCI than HC (Pearson's χ2 test p<0.05; post hoc: HC<MCI; AD<MCI) and CIRS total score 
which was higher in MCI with respect to AD and HC (0.5 ± 0.2 vs. 0.3 ± 0.2 vs. 0.4 ± 0.2, p= 0.003; 
post hoc: HC<MCI; AD<MCI).  
MNA global and total score were lower in AD than in HC in both sexes; MCI did not differ from 
HC except for a lower MNA screening score in men and for a lower global score in women.   
Interestingly, when analyzing each MNA subitems, hydration (item M) resulted significantly 
reduced in AD with respect to MCI and HC (Pearson’s χ2 test; men p<0.05, women p<0.001).   
With regards to anthropometric measurements, AD of both sexes showed significantly lower 
arm and calf circumferences with respect to HC (women’s arm circumferences in multivariate GLM 
corrected for age: F 3.07, p <0.05; AD< MCI=HC). AD men had smaller waist circumferences than 
HC and MCI.  
The phase angle (PA), ratio of reactance to height (R/h) and ratio of impedance to height (Z/h) were 
significantly different between AD and HC in both sexes; AD women showed also a significantly 
lower ratio of reactance to height (Xc/h) than HC in the multivariate GLM with age used as a 
covariate (F 4.71, p <0.01). A higher ratio of reactance to height (R/h) and ratio of impedance to 
height (Z/h) was found in men with MCI with respect to HC.  
No statistically significant differences in bioelectrical parameters (PA, R/h, Xc/h, Z/h) were found 
between MCI women with and without depression.  
Unadjusted, partially adjusted and fully adjusted GLM showed overlapping results.  
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Given the small study sample, a sensitivity analysis with non-parametric tests (Kruskal-Wallis) was 
also performed and confirmed the results.  
No significant correlation emerged between AD disease duration (from disease onset) and 
nutritional assessment with MNA or bioelectrical parameters.  
Mean impedance vector and confidence ellipses are shown in Fig. 1A and 1B; statistical 
comparison of groups with Hotelling's T2 test, with the corresponding p value and Mahalanobis 
distance D are also reported.  
 
Fig. 1 A Distribution of confidence ellipses of men with Alzheimer’s dementia (AD), Mild 
Cognitive Impairment (MCI) and healthy controls (HC). B Distribution of confidence ellipses 
of women with Alzheimer’s dementia (AD), Mild Cognitive Impairment (MCI) and healthy 
controls (HC).  
 
The 95% confidence ellipses significantly differed between HC and AD (Hotelling’s T2 test: men = 
18.2; women = 16.9; p < 0.001). The ellipses of AD shifted toward the inferior region of the RXc 
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graph, corresponding to low body cell mass (Fig 1). The ellipses of MCI were closer to AD than 
HC, and significantly differed from HC (Hotelling’s T2 test: men = 10.6; women= 7.9; p < 0.05).  
The effect size (Anon, 2013) computed for groups (AD vs. HC), by adjusting the calculation of the 
pooled standard deviation with weights for the sample sizes are reported in table 3.  
Table 3. Effect size (CI 95%) of bioelectrical variables for Alzheimer’s disease (AD) patients 
with respect to healthy controls (HC).  
Groups Bioelectrical variables Effect size (95% CI) 
PA(°) 1.066 (0.488 – 1.643) 
 
AD vs. HC (men) Z/h (Ώ/m) -0.9 (-1.539 –  -0.397) 
PA(°) 1.066 (0.539 – 1.592) 
 
AD vs. HC (women) Z/h (Ώ/m) -0.767 (-1.277 – -0.258) 
 
 
 
Longitudinal part of the study 
 
AD 
 
After 8.7 ± 3.6 months, AD showed overall a significant worsening of MiniMental State 
Examination (MMSE) (19.4 ± 4.5 vs.18.3 ± 5.2, p = 0.04), Clinical Dementia Rating Scale (CDR) 
(1.7 ± 0.1 vs. 2.1 ± 0.1, p < 0.001), Activity of Daily Living (ADL) scores (4.0 ± 0.3 vs. 3.6 ± 0.3, p 
= 0.02). Anthropometric and bioelectrical variables did not significantly change during follow-up  
except for women’s arm circumference (24.2 ± 2.7 vs. 23.6 ± 2.7, p = 0.049) Table 4 and 5 show 
clinical, functional and nutritional variables at baseline and follow-up in AD for males and females 
respectively.  
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Table 4. Clinical, functional and nutritional variables in 15 men with AD at baseline (T0) and 
follow-up (T1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are expressed as means ± standard deviation 
 
Table 5. Clinical, functional and nutritional variables in 25 women with AD at baseline (T0) 
and follow-up (T1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are expressed as means ± standard deviation 
 
AD  T0 AD  T1 p 
MMSE  20.0 ± 4.6 18.7 ± 5.0 ns 
ADL (lost) 2.4 ±  1.8 1.3 ±  1.8 ns 
IADL (lost) 4.1 ±  1.5 4.1 ±  1.6 ns 
CDR 1.8 ±  2.1 2.1 ± 0.7 ns 
BMI (kg/m2) 25.1 ±  3.4 25.1 ±  3.2 ns 
Arm circumference (cm) 24.1 ±  3.2 24.7 ± 3.7 ns 
Calf circumference (cm) 32.7 ±  2.4 32.5 ± 2.7 ns 
Waist circumference (cm) 91.8 ±  10.7 91.7 ±  9.0 ns 
Rz/h (Ώ/m) 256.5 ± 36.3 250.5 ± 36.3 ns 
Xc/h (Ώ/m) 26.0 ± 4.5 25.8 ± 4.9 ns 
PA (°) 5.7 ± 0.5 5.8 ±  0.7 ns 
Z/h (Ώ/m) 257.8 ± 36.4 251.8 ± 36.5 ns 
 AD  T0 AD  T1 p 
MMSE  19.2 ± 4.4 18.1 ± 5.4 ns 
ADL (lost) 1.8 ± 1.8 2.5 ±1.8 0.003 
IADL (lost) 5.0 ± 2.2 5.6 ± 1.6 0.042 
CDR 1.6 ± 0.7 2.1 ± 0.7 0.002 
BMI (kg/m2) 24.2 ± 3.3 23.9 ± 3.5 ns 
Arm circumference (cm) 24.2 ± 3.3 23.9 ± 2.7 0.038 
Calf circumference (cm) 30.8 ± 3.0 30.4 ± 3.2 ns 
Waist circumference (cm) 83.5 ± 9.5 82.7 ± 10.3 ns 
Rz/h (Ώ/m) 321.1 ± 32.3 323.9 ± 39.8 ns 
Xc/h (Ώ/m) 31.1 ± 5.1 32.0 ± 5.0 ns 
PA (°) 5.6 ± 0.8 5.6 ± 0.7 ns 
Z/h (Ώ/m) 322.7 ± 32.4 326.2 ± 39.2 ns 
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A linear regression model with phase angle as dependent variable and time of follow-up and MMSE 
score change over time as independent variables did not yield significance.  
MCI 
Forty-three MCI (28 females, 15 males) were recruited and followed up for 14.4 ± 8.6 months; 8 (6 
females, 2 males) of them progressed to AD, amongst them 3 (2 females, 1 male) also showed a 
mild vascular encephalopathy at MRI; no other forms of dementia have been diagnosed during 
follow-up. Due to the limited number of males progressed, we have only explored bioelectrical 
characteristics at baseline of females MCI (Table 6).  
 
Table 6. Baseline clinical and bioelectrical variables in the whole sample of MCI, in stable 
MCI at follow-up and in MCI progressed to AD (females).  
 MCI stable 
(N = 22) 
MCI progressed to AD 
(N = 6*) 
p 
Age 78.3 ± 5.0 76.5 ± 3.0 n.s. 
Education 5.5 ± 2.4 10.0 ± 4.1 0.006 
MMSE score 26.1 ± 2.5 24.3 ± 2.9 n.s. 
IADL lost 0.1 ± 0.4 0.8 ± 1 n.s. (0.064) 
CIRS total score 0.45 ± 0.23 0.54 ± 0.25 n.s. 
CIRS 2 2.9 ± 1.6 3.5 ± 1.6 n.s. 
BMI 25.1 ± 5.1 24.6 ± 2.4 n.s. 
CB 24.8 ± 2.9 24.5 ± 3.5 n.s. 
CP 32.1 ± 3.6 31.5 ± 3.1 n.s. 
CA 83.3 ± 11.8 87.8 ± 7.4 n.s. 
Rz/h 305.7 ± 38.4 326.4 ± 42.9 n.s. 
Xc/h 31.5 ± 5.6 29.8 ± 3.3 n.s. 
PA 5.9 ± 1.0 5.2 ± 0.6 n.s. (0.069) 
Z/h 307.3 ± 38.4 327.8 ± 42.9 n.s. 
*2 of them received a diagnosis of AD associated with mild vascular encephalopathy 
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The effect size computed for groups (MCI vs. HC), by adjusting the calculation of the pooled 
standard deviation with weights for the sample sizes, are reported in table 6.  
Table 7. Effect size (CI 95%) of bioelectrical variables for Mild Cognitive Impairment (MCI) 
subjects with respect to healthy controls (HC).  
Groups Bioelectrical variables Effect size (CI 95%) 
PA(°) 0.286 (-0.335 – 0.926) 
  MCI vs. HC (men) 
Z/h (Ώ/m) -1.034 (-1.709 – -0.360) 
PA(°) 0.833 (0.240 – -1.426) 
MCI vs. HC (women) Z/h (Ώ/m) -0.461 (-1.038 – -0.116) 
 
Discussion 
Patients with mild-moderate AD showed a significantly different nutritional status with respect to 
cognitively HC in anthropometric measurements and bioelectrical parameters of BIVA; MCI 
subjects demonstrated an intermediate pattern of BIVA vectors between mild-moderate AD and HC 
and, in particular, female MCI who progressed to clinically evident AD had a lower PA (which is 
the most important impedance parameter indicating soft tissue) than stable MCI. Bioelectrical 
parameters appear to be stable when BIVA was repeated during AD follow-up (8.7 ± 3.6 months).  
While our findings in AD patients are consistent with available literature, to our knowledge this is 
the first study which has analysed body composition by BIVA in subjects with MCI. In 2010 Buffa 
et al. (Buffa et al., 2010) first applied BIVA to AD patients and found significantly lower PA in 
patients with mild-moderate AD of both sexes with respect to controls; furthermore they found that 
women with severe AD showed reduced tissue mass and dehydration when compared with AD 
patients with mild-moderate disease severity; no longitudinal data were available.  
In 2012 the same group (Saragat et al., 2012) detected higher impedance values (Z/h and R/h) in AD 
patients than in controls and suggested an increase of fat component with respect to the muscle mass 
along with psycho-functional decline: this hypothesis was supported by replication of these findings 
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with the technique of “specific” BIVA (Buffa et al., 2014), where “specific” values (resistivity [Rsp] 
and reactivity [Xcsp], Ω ·  cm)  were obtained by multiplying R and Xc by a correction factor which 
includes an estimate of the cross-sectional area of the body.  
We have noticed that nutritional status of our HC and AD population completely differs from 
Sardinian population enrolled in the studies of Saragat and Buffa (Saragat et al., 2012; Buffa et al., 
2014), since we detected significantly lower impedance values (R/H, Xc/H and Z/h) in both 
populations. This finding underlines the importance of recruiting a local control population in 
nutritional studies, because differences in body composition and hydration status can be conspicuous 
even among regions of the same country and may be linked to different dietary habits. 
Recently, it has been suggested that BIVA could reflect dementia-related changes in body 
composition better than BIA in a study which involved men with (undefined subtype of) dementia 
(Camina Martín et al., 2015). This statement could be mainly due to the fact that fat free mass has 
not the same hydration percentage (73%) as conventional BIA presupposes. This is the reason why 
we preferred to avoid calculating fat mass (FM) and fat free mass (FFM) in the present study. Our 
findings of such alteration of electrical properties of tissues in AD patients support the hypothesis of 
their lower muscle mass and consequently higher fat mass. During aging process, reduction of body 
weight, height and FFM, associated with an increase in FM is well documented (Doherty, 2003).  
However, body composition of elderly subjects with AD differs from that of cognitively healthy 
elderly subjects (Renvall et al., 1993): lower arm and calf circumferences and bioelectrical 
differences in AD patients with respect to controls in the present study corroborate this hypothesis. 
Right side displacement of impedance vector in AD group indicates lower values of body cell mass 
(Withers et al., 1999) and therefore worse nutritional parameters.  
Nutritional status found with BIVA in AD tends to remain relatively stable during follow-up (after a 
mean follow-up of 9 months); no previous studies have investigated the presence of an eventual 
variability of BIVA parameters during AD follow-up. This result could be interpreted in two ways: 
on the one hand follow-up might have been too short to identify any significant difference, but on 
the other hand a possible alternative explanation is that body composition change may occur earlier, 
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namely in a prodromal phase (MCI due to AD) and then remain stable or progress slowly. So even if 
BIVA pattern appears able to distinguish AD from HC, it does not seem useful as a marker of 
disease progression (staging biomarker), at least in a short time interval suitable for change analysis 
in clinical trials. Moreover, body composition differences in AD may appear during early phase of 
disease (MCI) and then decline slowly: the different BIVA pattern shown by Buffa et al. is the result 
of a cross-sectional comparison.  
MCI could be a preclinical phase of AD or other type of dementia since it has a progression rate 
around 10–15% per year in memory clinics (Petersen et al., 2014). Our previous works showed that 
a low BMI, as well as weight loss, could predict progression of MCI and several biologically 
plausible hypotheses have been previously proposed (Cova et al., 2016a, 2016b). In the cross-
sectional part of the present study we found significantly different confidence ellipses in RXc graph 
with respect to controls, meaning decreased conductive tissue mass (tendency towards sarcopenia); 
this suggests that soft tissue mass could decrease with cognitive impairment independently from 
aging process. Analysis of body composition with BIVA could then detect early changes in body 
composition which could reflect early systemic manifestation of the AD process (Morris et al., 
2014) at MCI stage of disease, before anthropometric change becomes evident. Indeed, after a 
follow-up of a mean of 14 months, female MCI who progressed to clinically evident AD showed a 
lower PA than stable MCI (which tend to be significant). This last finding represents a very 
preliminary result, since we know that MCI subjects should be followed up longer to capture all 
cases which will develop dementia (Petersen, 2004).  
This result further supports the hypermetabolic hypothesis of weight loss in AD (see above) (Sergi 
et al., 2013). Moreover, in our cohort of AD we have found approximately a 60% of insulin 
resistance (Homeostasis Model Assessment of IR [HOMA] index 2 > 1,4) (Geloneze et al., 2009) in 
available blood samples (16 patients). HOMA index is a validated method to measure insulin 
resistance from fasting glucose and insulin. Few HOMA index were available for our MCI cohort 
(only for 5 subjects, 4 of them showed insulin resistance). High insulin concentrations are 
implicated in the neuropathological mechanisms underlying the neuronal damage of AD 
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(Kandimalla et al., 2017).  In a study of 2015, subjects affected by amnestic MCI who converted to 
AD showed higher insulin sensitivities indexes than stable MCI (Fiammetta et al., 2015): MCI due 
to AD is proposed as an “early biochemical active disease stage” where hyperinsulinemia, 
glycoxidation and pro-amyloidogenic status are at the highest rate, whereas clinically manifest AD 
could represent a final stage of a glycoxidative cascade, a process which possibly began two decades 
earlier.  
There is growing evidence that brain insulin levels and insulin-like growth factor (IGF) resistance 
and mediated metabolic imbalance may be considered as critical etiologic factors in AD; this 
suggests that these indices and their consequences (i.e. oxidative stress, neuro-inflammation, and 
reduced neuronal plasticity) should be included in biomarker panels for AD (Lee et al., 2013). Our 
study suggested a possible role of BIVA parameters in this context.  
It is also clear that dietary habits influence glucose-insulin homeostasis, pathways of weight 
regulation, visceral adiposity, the gut microbiota as well as oxidative stress, and inflammation 
(Solfrizzi et al., 2017).  Recent findings suggest that AD patients have a higher detection 
threshold for all tastes and a higher recognition threshold for sweet (Sakai et al., 2016); this result 
may explain their common increased desire for sweet taste, which is known also to grow when 
body requires more energy (due to a hypermetabolic state). Moreover, dorsolateral prefrontal 
cortex dysfunction in AD could be involved in sugar cravings. Different nutritional “trajectories” 
may be postulated in different subtypes of AD and perhaps from other dementia types, due to 
different shares of each potential pathological stressors  (Mravec et al., 2017)and which become 
apparent in body composition changement. Diet is one of the main factor which can influence 
ageing of the brain and subsequent age-related diseases. It is well known that certain nutrients, 
such as polyphenolic compounds contained in fruits and vegetables (Dai et al., 2006), 
polyunsaturated fatty acids, some vitamins (Luchsinger and Mayeux, 2004) may play a protective 
role in the ageing brain and in pathogenesis of AD. Also voluptuary habits, such as alcohol, coffee 
and chocolate consumption, due to their content in neuroactive substances, may interfere with 
cognitive processes. Alcohol may impair blood glucose control: if a malnourished or a fasting 
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person drink alcohol, hypoglycemia can arise and subsequently a depletion of stored sugar needed 
for energetic cellular functions occurs (Patel, 1989). The neuroprotective effect of 
methylxanthines (caffeine, theobromine and theophylline) is well-known (Oñatibia-Astibia et al., 
2017) so much that xanthine derived-drugs have been studying for AD therapy. It is very complex 
to understand the long-life effect of a complex diet, but it is unreasonable not to suppose its key 
role in the pathogenesis of several disease such as AD. Although a healthy diet may provide 
bioactive nutrients able to preserve biological functions and potentially to prevent disease 
development, different food processing and cooking methods are also important elements to 
considered. Whereas dietary recommendations for many years focused on single vascular risk 
factors prevention and treatment (e.g., hypertension, blood cholesterol, etc.) and current 
nutritional discussions often concern total calories and obesity, the full health impact of diet 
extends far beyond these themes, opening the way to consider a diet-related prevention of 
dementia and AD.  
 
Our results should be interpreted within the context of the limitations of the study.  First, the sample 
size was small; therefore, further studies with a larger sample size are required to confirm our data. 
Second, our study lacks other putative biomarkers’ investigation; however, the subjects classified as 
MCI respected international core clinical criteria of 2011 (Albert et al., 2011).  
 
The strengths of our study are the clinical setting where the study took place, which allows an 
optimal characterization of subjects with MCI and AD from a psychometric point of view; 
furthermore, this setting facilitated detailed baseline collection of several potential confounding 
variables (comorbidities – particularly with regard to metabolic disorders and depression – and 
treatments). Finally, participants of this study are representative of those who routinely consult 
memory clinics. 
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Increasing the cohort of MCI subjects and their longitudinal observation will provide further 
information to allow generalization to populations of MCI attending memory clinics and to 
understand if a BIVA pattern indicating a worse nutritional status could be an early and sensitive 
marker of progression to dementia or specifically to AD in MCI subjects. Further studies will be 
needed to evaluate nutritional status and bioimpedance analysis patterns in other types of dementia 
than Alzheimer’s.  
 
Considering the differences found in MNA scores among different cognitive groups, we suggest 
implementing clinical practice of cognitively impaired patients with such a simple questionnaire, 
also to address nutritional advice when malnutrition is suspected.  
 
In summary, since little is known about nutritional status of MCI subjects, our work contributes to 
the growing research interest in this area. In any cross-sectional study, we cannot discriminate the 
direction of causality; longitudinal data provided are preliminary. Our finding should be considered 
tentative until future studies confirm or disprove our observations. 
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